Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 1
Interventions: Technosphere insulin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin aspart, insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Insulin aspart, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 10 Years to 25 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes
Interventions: aspart, aspart- Insulin; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 28
States / cities: Little Rock, Arkansas • Inglewood, California • San Francisco, California + 23 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin glulisine, Insulin lispro, Insulin aspart; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 26 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 92
States / cities: Birmingham, Alabama • Goodyear, Arizona • Concord, California + 81 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: inhaled human insulin, insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 86
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, Insulin aspart, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 77
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more

Conditions: Type 1 Diabetes
Interventions: MiniMed 780G System; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 7 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Little Rock, Arkansas • Fresno, California • Sacramento, California + 12 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: biphasic insulin aspart, insulin glargine, metformin, pioglitazone; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 27
States / cities: Concord, California • Los Angeles, California • Walnut Creek, California + 20 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 13 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more

Conditions: Diabetes Mellitus, Type II
Interventions: Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Concord, California • Encino, California • Escondido, California + 18 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 33
States / cities: Concord, California • Temecula, California • Ventura, California + 30 more

Conditions: Diabetes Mellitus, Type 2, Diabetes
Interventions: Metformin, Detemir, Liraglutide, Insulin Aspart; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec/insulin aspart, insulin aspart, insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 19 more

Conditions: Pharmacokinetics, Pharmacodynamics
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Fast-acting insulin aspart, iLet™; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, basal insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 32
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 27 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: Faster-acting insulin aspart, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

Detemir: Role in Type 1 Diabetes

Carbohydrate Consumption as a Factor in Aspart Dosing

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes